Clinical Trial

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-10; most recent amendment 2026-06-26.
Trial Details
NCT Number NCT07285798
Lead Sponsor Bristol-Myers Squibb
Conditions Irritability Associated With Autism Spectrum Disorder
Enrollment 176 participants
Start Date 2026-09-11
Primary Completion 2029-08-04 (estimated)
Study Completion 2029-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-30